ISRCTN48954234已完成不适用

Efficacy of zinc (given as an adjunct) in the treatment of severe and very severe pneumonia in hospitalised children 2 to 24 months of age

The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)0 个研究点目标入组 492 人开始时间: 2007年4月23日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Children 2 months and up to 24 months of age presenting with a cough or difficult breathing of less than seven days duration with:
•1. Fast breathing:
•1.1. Greater than 50 breaths per minute in children less than 24 months
•1.2. Greater than 40 breaths per minute in children 24 to 35 months
•2. Crepitations (on auscultation)
•3. Presence of chest indrawing or any general danger sign, i.e., lethargy or inability to drink or central cyanosis (defined as severe pneumonia)

•Children with any of the following features will be excluded:
•1. Congenital malformations, e.g., hydrocephalus, structural Central Nervous System (CNS) malformation
•2. Known structural defects, which interfere with feeding, for example:
•2.1. Cleft palate
•2.2. Oesophageal abnormalities
•2.3. Intestinal atresia and stenosis
•2.4. Malrotation of the gut
•2.5. Anorectal malformation
•3. Subjects requiring ventilation or ionotropic support
•4. Known inborn error of metabolism
•5. Chronic disorders of other organs, e.g., neonatal cholestasis, chronic renal failure, pre-existing seizure disorder
•6. Infants born of known Human Immunodeficiency Viurs (HIV) mothers
•7. Congenital heart disease
•8. Known case of bronchial asthma
•9. Active measles (fever and rash)
•10. Severe malnutrition requiring separate medical attention
•11. Children receiving zinc supplements
•12. Children documented to have received intravenous antimicrobials for more than 48 hours for current illness

发起方

The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)